On Stewardship of Business and Science
To date, the scientific investigation of cannabis as a botanical therapy has been restricted to two paradigms:
- Those investigations which align themselves with the motivations of academic research
- The remainder which serve strictly commercial purposes in the current medical cannabis marketplace.
For instance, a motivation of academic research which tends to reflect departmental pressures is that which heavily focuses on publishing peer reviewed journal articles, a paradigm coined “publish or perish” in many institutions.
On the other hand, commercial cannabis laboratories are only capable of producing information that is of immediate commercial value to the current market. Even the best selling test, the “potency analysis,” is used primarily as a promotional factor at the point of sale, whereas health safety related tests ought to be the main focus.
All aspects of medical cannabis are underrepresented by good data and unbiased facts
Moreover, as research and development in manufacturing becomes more sophisticated, it’s apparent that the current commercial laboratories are not equipped to service the innovative process for manufacturers.
Our Role as Ganjiers in Cannabis Science
As “Ganjiers” and innovators in our field, it is our goal to investigate cannabis in a way that allows a much better understanding of the physical and therapeutic nature of the botanical drug. In doing so, we seek to provide unmatched value in both the sciences and the commercial market by adding a new paradigm to the approach to manufacturing: that which will be relevant in the future commercial medical cannabis marketplace.
Further, we seek to help steer the policies in the most rational and, therefore, predictable manner and, in doing so, hedge the major financial risk in long-term investments. It is our opinion that policy risk is the major factor keeping investments either short sighted or highly irrational, focusing on brand recognition and short term revenue but lacking the foresight of growth and market share based on product innovation.
In contrast, we recognize the clear trend in the market demand for dose calibration and superior drug delivery methods as well as the desire to find the correct proportion of constituents that serve the therapeutic purpose best for them.
It’s also apparent that we can take advantage of the lacking and misguided regulatory climate by approaching the therapeutic paradigm in a technologically modern, rational, and scientifically driven manner.
How can sticking to a purely scientific process support a profit motive?
The simple answer is that all aspects of medical cannabis are underrepresented by good data and unbiased facts. By addressing the information deficit, we will be able to evaluate market trends as the industry matures, manufacture drugs and drug delivery methods with a higher level of specificity, and provide an all-around higher value to the consumer by giving them not only the right questions to ask, but also the answers.